LLY

884.96

-0.04%↓

NVO

141.87

+0.6%↑

UNH

482.42

-0.43%↓

JNJ

148.65

+0.6%↑

MRK

130.24

+0.4%↑

LLY

884.96

-0.04%↓

NVO

141.87

+0.6%↑

UNH

482.42

-0.43%↓

JNJ

148.65

+0.6%↑

MRK

130.24

+0.4%↑

LLY

884.96

-0.04%↓

NVO

141.87

+0.6%↑

UNH

482.42

-0.43%↓

JNJ

148.65

+0.6%↑

MRK

130.24

+0.4%↑

LLY

884.96

-0.04%↓

NVO

141.87

+0.6%↑

UNH

482.42

-0.43%↓

JNJ

148.65

+0.6%↑

MRK

130.24

+0.4%↑

LLY

884.96

-0.04%↓

NVO

141.87

+0.6%↑

UNH

482.42

-0.43%↓

JNJ

148.65

+0.6%↑

MRK

130.24

+0.4%↑

Search

BioCryst Pharmaceuticals Inc

Closed

Sector Healthcare

6.39 4.07

Overview

Share price change

24h

Current

Min

6.29

Max

6.45

Key metrics

By Trading Economics

Income

39M

-36M

Sales

6.7M

93M

EPS

-0.28

Profit margin

-41.674

Employees

536

EBITDA

-20M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+149.22 upside

Dividends

By Dow Jones

Next Earnings

1 sie 2024

Market Stats

By TradingEconomics

Market Cap

41M

990M

Previous open

2.32

Previous close

6.39

News Sentiment

By Acuity

50%

50%

98 / 369 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Weak Bullish Evidence

BioCryst Pharmaceuticals Inc Chart

Related News

21 cze 2024, 17:53 UTC

Major Market Movers

Shares of Four U.S. Banks Slide as Regulator Finds Living Wills Weaknesses

22 cze 2024, 23:00 UTC

Earnings

The Crazy Economics of the World's Most Coveted Handbag -- WSJ

22 cze 2024, 23:00 UTC

Earnings

The Crazy Economics of the World's Most Coveted Handbag -- WSJ -2-

22 cze 2024, 10:00 UTC

Top News
Earnings

Nvidia Is No Cisco, but It Is Getting Expensive -- Heard on the Street -- WSJ

22 cze 2024, 09:30 UTC

Earnings

Delivery Drivers Got Higher Wages. Now They're Getting Fewer Orders. -- WSJ

22 cze 2024, 08:20 UTC

Market Talk

Financial Services Roundup: Market Talk

21 cze 2024, 23:45 UTC

Acquisitions, Mergers, Takeovers

Nvidia Is Surging. Why That's a Problem for a Tech ETF. -- Barrons.com

21 cze 2024, 22:19 UTC

Top News

Jury Convicts Milken Protégé Terren Peizer of Insider Trading -- WSJ

21 cze 2024, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

21 cze 2024, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

21 cze 2024, 20:37 UTC

Top News

S&P 500 Clinches Third Straight Weekly Gain -- WSJ

21 cze 2024, 20:08 UTC

Top News

Apple Says Regulatory Concerns Might Prevent Rollout of AI Features in Europe -- Update

21 cze 2024, 19:22 UTC

Market Talk

Oil Futures Post Weekly Gain on Demand Expectations -- Market Talk

21 cze 2024, 19:04 UTC

Market Talk

Higher Output, Easing Heat Pressure U.S. Natural Gas -- Market Talk

21 cze 2024, 18:53 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Home Depot to Benefit from Diversified Consumer Base After Latest Acquisition -- Market Talk

21 cze 2024, 18:41 UTC

Market Talk

Gold Slides in Cautious Market -- Market Talk

21 cze 2024, 18:41 UTC

Market Talk

Global Equities Roundup: Market Talk

21 cze 2024, 18:34 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

21 cze 2024, 18:34 UTC

Market Talk

Mexico's Peso Gets Lift From Picks for New Cabinet -- Market Talk

21 cze 2024, 17:53 UTC

Earnings

Delta Stock Is a Winner. Its CEO Explains Why It Can Fly Higher. -- Barrons.com

21 cze 2024, 17:43 UTC

Market Talk

U.S. Oil Rig Count Falls to 485 -- Market Talk

21 cze 2024, 17:32 UTC

Top News

Apple Says Regulatory Concerns May Prevent Rollout of AI Features in Europe -- WSJ

21 cze 2024, 17:16 UTC

Acquisitions, Mergers, Takeovers

Penn Could be Getting a Buyout Offer. Wall Street Doesn't Agree on What It Means for the Stock. -- Barrons.com

21 cze 2024, 17:06 UTC

Top News

Regulators Cite Big Banks, Including Goldman Sachs and JPMorgan, Over Living Wills -- WSJ

21 cze 2024, 16:29 UTC

Market Talk

Strong USD a Pressure Point for Grains -- Market Talk

21 cze 2024, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

21 cze 2024, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

21 cze 2024, 15:46 UTC

Market Talk

Gold Futures Slump as Strong U.S. Business Activity Boosts Dollar -- Market Talk

21 cze 2024, 15:40 UTC

Market Talk

Citi Sees Chance of Sustained Oil Price Rally -- Market Talk

21 cze 2024, 15:30 UTC

Market Talk

Canadian Core Retail Sales Rebound in April Seen as Encouraging -- Market Talk

Peer Comparison

Price change

BioCryst Pharmaceuticals Inc Forecast

Price Target

By TipRanks

149.22% upside

12 Months Forecast

Average 16 USD  149.22%

High 30 USD

Low 6 USD

Based on 7 Wall Street analysts offering 12 month price targets forBioCryst Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

7 ratings

6

Buy

1

Hold

0

Sell

Technical Score

By Trading Central

6.1 / 7.65Support & Resistance

Short Term

Weak Bullish Evidence

Intermediate Term

Strong Bullish Evidence

Long Term

Strong Bearish Evidence

Sentiment

By Acuity

98 / 369 Ranking in Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About BioCryst Pharmaceuticals Inc

BioCryst Pharmaceuticals, Inc. discovers oral and small-molecule medicines that treat rare diseases in which unmet medical needs exist and an enzyme plays the key role in the biological pathway of the disease. ORLADEYO (berotralstat) is an oral, once-daily therapy that is approved in the United States, the European Union, Japan, and the United Kingdom for the prevention of hereditary angioedema attacks in adults and pediatric patients 12 years and older. The Company has several ongoing development programs, including BCX9930, an oral Factor D inhibitor for the treatment of complement-mediated diseases; BCX9250, an activin receptor-like kinase-2 inhibitor for the treatment of fibrodysplasia ossificans progressiva, and galidesivir, an antiviral drug for Marburg virus disease and Yellow Fever. RAPIVAB (peramivir injection) is a viral neuraminidase inhibitor for the treatment of influenza, has received regulatory approval in the United States, Canada, Australia, Japan, Taiwan and Korea.